Erudio Healtherudio.com
Drug
Inca33890 trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying inca33890: INCB161734-101. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| INCB161734-101 NCT06179160 · Incyte Corporation | KRAS G12D-mutated advanced or metastatic solid tumors | Phase 1 | 32 | 18 | Focused | Nov 20, 2026 | Preview |